The topline results of this phase 3 trial with pelacarsen are expected in 2026 (i.e., later than initially expected) due to the small number of events observed (it is an event-driven study), and if positive, then it will give the green light for the approval of first-in-class drug therapy specifically targeting elevated Lp(a) levels, an inherited, independent, and causal risk factor for ASCVD. Here, LPA is linked to atherosclerosis.